Abstract
Background Gastric cancer is the fourth most common cancer worldwide. Despite advances in diagnosis of gastric cancer, the prognosis at advanced stage of disease with the current chemotherapeutic treatment strategies remains poor. Hence, new agents and molecular targets for gastric cancer therapy are desperately needed. Sphingosine kinase 1 represents a promising novel target for anti-cancer therapy. However, the most common used small molecule inhibitors of SphK are unspecific inhibitors of SphK1. Here we investigated the effect of targeted downregulation of SphK1 by locked nucleic acid antisense oligonucleotides (LNA-ASO) in gastric cancer cell lines.
Highlights
Gastric cancer is the fourth most common cancer worldwide
14th Scientific Symposium of the Austrian Pharmacological Society (APHAR) Andrea Laslop and Thomas Griesbacher Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1471-2210-8-S1-info.pdf
We investigated the effect of targeted downregulation of SphK1 by locked nucleic acid antisense oligonucleotides (LNA-ASO) in gastric cancer cell lines
Summary
Address: 1Department of Clinical Pharmacology, Medical University Vienna, 1090 Vienna, Austria and 2Santaris Pharma A/S, 2970 Hørsholm, Denmark. Published: 5 November 2008 BMC Pharmacology 2008, 8(Suppl 1):A51 doi:10.1186/1471-2210-8-S1-A51. 14th Scientific Symposium of the Austrian Pharmacological Society (APHAR) Andrea Laslop and Thomas Griesbacher Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1471-2210-8-S1-info.pdf
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
